STRO Sutro Biopharma, Inc.

$20.48

Sutro Biopharma, Inc. (STRO) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $2.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.2% since its last earnings release on August 12, 2026.

Sutro Biopharma Missed Consensus Estimates
Wednesday, August 12, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($2.01)
Rev est $6.61M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $21.15

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Sector

Healthcare

Industry

Biotechnology